News

The European Commission has published a new version of the Questions & Answers (Q&A) document on “Safety Features for Medicinal Products for Human Use (V.21)”.

Ko izgaismo un kādas mācības sniedz Ozempic gadījums? Visa zāļu verifikācijas sistēmas kopiena Eiropā ļoti uzmanīgi seko “Ozempic gadījumam”, un Latvija nav izņēmums. Lai arī šobrīd mūsu valstī nav konstatēti šo zāļu viltojumi, mums nav nekādu garantiju, ka tas nevar notikt rīt vai pēc mēneša.

The European Medicines Verification Organisation (EMVO) has launched the EMVS Community Newsletter - edition April 2024. This month, newsletter focusing on Data Quality, featuring insights from EMVO, the Dutch NMVO, Accord Healthcare, and end-user perspectives from the healthcare sector.

While setting up the Lithuanian Medicines Verification Organization (NVVO) came with its challenges in the beginning, ever since its founding back in 2017 we have not swayed from our goal: to ensure the safety of medicines for patients.

The European Medicines Verification System, operating since 2019 in accordance with the EU Directive and Delegated Regulation, is a comprehensive, pan-European system covering all EU and EEA countries, connecting 2,800 pharmaceutical companies, 4,000 wholesalers, 110,000 pharmacies and 6,000 hospital pharmacies online, including all Latvian end users.

Kamēr Eiropā turpinās izmeklēšana Ozempic gadījumā, arī ASV Pārtikas un zāļu pārvalde (FDA) turpina izmeklēt viltotu Ozempic (semaglutīda) injekciju 1 miligramu (mg) likumīgajā ASV zāļu piegādes ķēdē un ir konfiscējusi tūkstošiem produkta vienību.